Background: Up to 80% of men and 50% of women have androgenetic alopecia (AGA), a non-scarring hair loss condition that is marked by a gradual shrinkage of the hair follicle, throughout adolescence and beyond puberty, Aim and objectives: This study aimed to assess the efficiency and security of using type A botulinum toxin (BTA) to treat androgenetic alopecia in males, Subjects and methods: This interventional research was conducted in Dermatology, Venereology and Andrology Department Outpatient Clinic, Al-Azhar University Hospital (Damietta) and Mubarak Hospital in Giza (Ministry of Heath). This study included 20 patients with androgenetic alopecia grade II-IV according to Norwood Hamilton criteria, Result: There was statistically significant decrease of vellous hair count between first session 48.6 to 39.7 second session and 31.25 at third session with percent of change is the highest between 1 st and 3 rd session (35.7%) then between second and third session (21.3%) and the lowest percent of change was detected between 1 st session and 2 nd session (18.3%).There was statistically significant increase of mean hair thickness between first & second session 56.30 & 66.20 and 78.2 at third session with percent of change is the highest between 1st and 3rd session (38.9%), then second and third session (18.1%) and between 1st session and 2nd session (17.6%), Conclusion: The results of the current research showed that BTA is a safe and successful treatment for AGA and has outstanding outcomes. These findings provide an innovative theoretical framework and therapeutic approach for the management of AGA,